Lupin share price down marginally in the early trade on October 7 after the company received five observations from USFDA for its Pune facility.
At 09:20am, Lupin was quoting at Rs 2,190.80, down Rs 6.80, or 0.31 percent, on the BSE.
The USFDA has recently completed a pre-approval inspection of a biotech facility in Pune, India, conducted from September 25 to October 4, 2024. The inspection concluded with five observations.
The company has stated that it is addressing these observations thoroughly and plans to respond to the USFDA within the required timeframe.
Catch all the market action on our live blog
In September, the company received three observations each of Pithampur Unit-1 API and finished product manufacturing facility.
Also, company entered into a non-exclusive patent licensing agreement with Takeda to bring Vonoprazan tablets, a novel gastrointestinal drug, to the Indian market.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
